Noble Life Sciences

Preclinical animal model utilizing murine peritonitis and cecal slurry models to evaluate antimicrobial and immunomodulatory agents for the treatment of sepsis.

Optimized peritonitis/sepsis mouse model to screen for new antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA).

Preclinical cotton rat animal model optimized for testing the efficacy of therapeutic agents, vaccines, and antivirals against respiratory syncytial virus (RSV) infection.

An optimized cotton rat animal model for influenza virus infection used for antiviral testing, vaccine development, and studying virus replication and pathogenesis.

Preclinical biodistribution study services for cell and gene therapy products utilizing absolute qPCR and RT-qPCR quantification to comply with GLP guidelines.

Full-service preclinical contract research organization offering GLP and non-GLP services, including safety and efficacy testing, for the development of drugs, vaccines, and medical devices.

Custom polyclonal antibody services using a variety of animal species designed to maximize antibody production for GLP preclinical studies and vaccine potency testing.

Noble Life Sciences offers a wide range of GLP testing services to ensure both the efficacy and safety of medical devices with expertise in orthopaedic, cardiovascular, trauma, and wound models.

Comprehensive preclinical toxicology testing services designed to assess drug safety and support IND approval applications.

Preclinical oncology and immuno-oncology services including cancer preclinical animal model testing, in vivo cancer models, OncoDiversity Cell Line Panel, and Pharmacodynamic Models.

Support for adoptive cell therapy, NK cell, and gene-modified cell therapy development.

Comprehensive preclinical testing services for orthopedic devices, implants, joint models, bone defect models, and spinal fusion models.

Comprehensive portfolio of patient-derived xenograft (PDX) models that replicate the heterogeneity, genetic integrity, and tumor microenvironment of human cancers for preclinical research.

Immunocompetent tumor models using murine-derived cancer cells allowing for immuno-oncology evaluations and testing of immune-based therapies.

Models designed to study systemic disease progression, immune interactions, and real-time tracking of metastasis in blood-based and metastatic settings.

Preclinical assessment services evaluating the location, persistence, and infection risks of viral vectors using real-time PCR, flow cytometry, and animal imaging.

A portfolio of xenograft and syngeneic models offered by Noble Life Sciences to assess the in vivo efficacy of novel CAR T cells and other cell therapy products.

Custom design, optimization, and validation of immunoassays using ELISA, ELIspot, and flow cytometry.

Customizable assay design, development, and validation services tailored to unique preclinical research needs, provided in partnership with Accelevir.

Evaluate human immune system interactions in oncology treatments.

State-of-the-art preclinical xenograft models using human tumor tissues implanted in immunocompromised mice to study cancer progression, metastasis, and therapeutic responses.

Preclinical testing services for medical devices across cardiovascular, orthopedics, trauma, wound healing, and drug delivery applications.

Patient-derived colon cancer xenograft (PDX) model established by implanting cryopreserved PDX fragments into transplant-compliant mouse hosts for preclinical drug screening and precision medicine.

Preclinical and drug development services for anti-infectious therapeutics, leveraging over 30 years of experience with BSL-2, BSL-3, and BSL-4 capabilities.

Infectious disease research solutions including SARS-CoV-2 research solutions, antiviral testing labs, and vaccine research for influenza, RSV, and sepsis pathogens.

Comprehensive medical device division providing surgical expertise and support utilizing quality equipment to advance cardiovascular disease and injury research, including GLP and non-GLP studies.

Preclinical vaccine discovery and development studies across a variety of mammalian species.

Comprehensive non-GLP toxicology services tailored to meet specific early-stage drug development needs with cost-effective flexibility and rapid insights.

A specialized bacterial infection model used to evaluate antibacterial agents and antibiotics in neutropenic subjects.

Integrated systems and consulting services for drug delivery product development, supporting preclinical research and medical device testing.

An infection model designed to study systemic bacterial infections and sepsis progression for therapeutic development.

A diverse collection of cell lines spanning multiple cancer indications used to screen drug candidates and determine molecular biomarker profiles.

DEXA scanning capabilities supporting preclinical applications for non-invasive precision measurement of bone density and body composition in live animals.

A syngeneic glioma model in C57BL/6 mice, this immunocompetent model is excellent for evaluating immune-based therapies, including checkpoint inhibitors and CAR-T cells.

Comprehensive dPCR contract research services providing unparalleled accuracy and valuable insights for nucleic acid quantification needs.

A syngeneic model in Balb/C mice that mimics metastatic breast cancer, ideal for immuno-oncology studies.

A salivary gland carcinoma model, providing insights into rare tumor types and testing targeted therapies.

Comprehensive quantitative polymerase chain reaction (qPCR) contract research services tailored for life sciences research, powered by the QuantStudio 6 system.

A clear cell renal cell carcinoma model that is highly responsive to VEGF/VEGFR targeted therapies.

A syngeneic model in Balb/C mice, widely used for immunotherapy studies in colorectal cancer.

A syngeneic model in C57BL/6 mice, providing valuable insights into immunotherapy strategies for lung cancer.

A Burkitt’s lymphoma model frequently used for immune-targeted therapies, including CAR-T and monoclonal antibodies.

A metastatic colorectal cancer model ideal for evaluating therapeutic agents targeting advanced disease stages.

A lymph node metastatic model, frequently used to investigate metastasis and therapeutic responses.

An HER2-positive breast cancer model frequently utilized in targeted therapy development, particularly HER2 inhibitors.

A robust HER2-positive model, useful for testing combination therapies involving HER2-targeted and chemotherapeutic agents.

A large cell lung carcinoma model, ideal for testing chemotherapies and combination regimens.

A reliable model for non-invasive bladder cancer studies, commonly used in immuno-oncology research to evaluate immune-targeted therapies.

A hepatocellular carcinoma model widely used for antiviral and liver cancer therapeutic studies.

Models for studying drug metabolism, liver cancer progression, and testing chemotherapeutics.

A model for oral squamous cell carcinoma, commonly used to evaluate therapeutic efficacy and resistance mechanisms.

Animal disease model for studying inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC).

A non-small cell lung cancer (NSCLC) model extensively used for studying tumor biology and therapeutic responses.

Preclinical diabetes studies using a variety of different models to determine the safety and efficacy of therapeutics.

A hypopharyngeal squamous cell carcinoma model ideal for studying head and neck cancers.

A human colorectal adenocarcinoma model known for its well-differentiated characteristics, commonly used in drug efficacy and resistance studies.

Live animal imaging system used for preclinical studies to non-invasively monitor and quantify tumor growth longitudinally in tumor bearing mice following CAR T cell treatment.

Mouse and ferret animal models used for influenza studies and vaccine development.

A well-characterized glioblastoma cell line ideal for investigating the efficacy of therapies targeting aggressive brain tumors.

A triple-negative breast cancer model known for its high invasiveness and metastatic potential.

A metastatic liver cancer model, suitable for studying aggressive phenotypes and therapeutic resistance.

A histiocytic lymphoma model for studying both tumor biology and therapeutic efficacy.

A widely used bladder cancer cell line ideal for evaluating the efficacy of therapeutics targeting urothelial carcinoma in xenograft models.

Genotoxicity karyotyping starting with as few as 100 cells per sample to provide a comprehensive understanding of genomic integrity.

A high-grade bladder cancer cell line frequently employed to study tumor progression and therapeutic response in invasive bladder cancers.

Single-cell analysis capabilities enabling the reliable detection of structural variations within heterogeneous cell populations.

Ventilated cages and dual HEPA-filtered racks for rodent housing.